Get the Stockscreener App
58.97
1.09%
-0.65
After Hours:
58.97
Rhythm Pharmaceuticals Inc stock is traded at $58.97, with a volume of 378.12K.
It is down -1.09% in the last 24 hours and up +0.14% over the past month.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
See More
Previous Close:
$59.62
Open:
$59.31
24h Volume:
378.12K
Relative Volume:
0.82
Market Cap:
$3.62B
Revenue:
$112.53M
Net Income/Loss:
$-258.91M
P/E Ratio:
-13.62
EPS:
-4.33
Net Cash Flow:
$-124.42M
1W Performance:
+4.67%
1M Performance:
+0.14%
6M Performance:
+39.47%
1Y Performance:
+48.35%
1-Day Range:
$57.66
$60.38
1-Week Range:
$55.85
$60.52
52-Week Range:
$35.17
$68.58
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
58.97 | 3.62B | 112.53M | -258.91M | -124.42M | -4.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
402.49 | 103.65B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.26 | 78.71B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
645.37 | 38.59B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
233.15 | 30.07B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.21 | 28.82B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-02-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
Principal Financial Group Inc. Has $1.71 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Principal Financial Group Inc. Buys 23,054 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Now Covered by Analysts at Jefferies Financial Group - Defense World
Jefferies starts Rhythm Pharmaceuticals with Buy on obesity potential - Yahoo Finance
Jefferies Financial Group Begins Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) - MarketBeat
Where are the Opportunities in (RYTM) - Stock Traders Daily
Stifel Financial Corp Has $1.04 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Receives Market Outperform Rating from JMP Securities - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Receives Buy Rating from HC Wainwright - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given "Market Outperform" Rating at JMP Securities - MarketBeat
Rhythm Pharmaceuticals' (NASDAQ:RYTM) investors will be pleased with their incredible 370% return over the last three years - Yahoo Finance
Rhythm Pharmaceuticals' (RYTM) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
FDA nod for Rhythm Pharma’s Imcivree - The Pharma Letter
Analysts Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Price Target at $64.67 - Defense World
Rhythm gets FDA approval for Imcivree for toddlers - MSN
Franklin Resources Inc. Purchases 26,739 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Barclays PLC Buys 47,166 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharma Modifies Trials of Genetic Obesity Medicine; Shares Drop - Marketscreener.com
Oppenheimer Initiates Coverage of Rhythm Pharmaceuticals (RYTM) with Outperform Recommendation - MSN
FDA Expands Rhythm Pharma Obesity Drug Approval to Younger Children - MarketWatch
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential - Benzinga
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® - GlobeNewswire
Rhythm Pharma's IMCIVREE Wins FDA Approval for Rare Obesity Treatment in Young Children - StockTitan
Rhythm Pharmaceuticals (NASDAQ:RYTM) Now Covered by Oppenheimer - MarketBeat
Forecasting The Future: 14 Analyst Projections For Rhythm Pharmaceuticals - Benzinga
Analysts Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Target Price at $64.67 - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Wellington Management Group LLP - MarketBeat
Ionq Inc (IONQ-N) QuotePress Release - The Globe and Mail
(RYTM) Trading Signals - Stock Traders Daily
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by State Street Corp - MarketBeat
Fmr LLC Raises Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
BNP Paribas Financial Markets Boosts Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Frazier Life Sciences Management L.P. Acquires 45,648 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
National Bank of Canada FI Has $17.89 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 11,058 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals: A Key Year Ahead (NASDAQ:RYTM) - Seeking Alpha
Rhythm Pharmaceuticals price target raised to $75 from $64 at JMP Securities - Yahoo Finance
(RYTM) Technical Data - Stock Traders Daily
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Goldman Sachs raises Rhythm Pharmaceuticals stock target by 12%, maintains Buy rating - Investing.com Canada
HighVista Strategies LLC Buys 23,064 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Defici - GlobeNewswire
Rhythm Pharma's IMCIVREE Gets UK Approval for Rare Obesity in Children as Young as 2 | RYTM Stock News - StockTitan
12,386 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Acquired by Intech Investment Management LLC - MarketBeat
Alkeon Capital Management LLC Buys 167,700 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Victory Capital Management Inc. Has $953,000 Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Healthcare of Ontario Pension Plan Trust Fund Raises Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Algert Global LLC - MarketBeat
25,063 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Purchased by Penserra Capital Management LLC - MarketBeat
Gastroparesis Drugs Market to Grow by USD 1.42 Billion (2024-2028), Diabetes Burden Boosts Growth, AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.27%
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):